Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy

NCT02515669 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02515669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02515669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Terminated
Start date
December 2, 2015
Completion date
April 15, 2020
Enrollment
43 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

muscular dystrophy (dmd)